AIM IMMUNOTECH INC. Debt Securities, Available-for-sale, Amortized Cost
AIM IMMUNOTECH INC. (AIM) had Debt Securities, Available-for-sale, Amortized Cost of $16.51 million as of 2021-09-30, per its 10-Q filed 2021-11-15.
Discontinued › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2022-03-31
- 2021-09-30: Debt Securities, Available-for-sale, Amortized Cost $16.51M.
- 2021-06-30: Debt Securities, Available-for-sale, Amortized Cost $16.34M.
- 2021-03-31: Debt Securities, Available-for-sale, Amortized Cost $14.99M.
- 2020-12-31: Debt Securities, Available-for-sale, Amortized Cost $15.92M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2021-09-30 | $16.51M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $16.34M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $14.99M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $15.92M 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |